<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04679818</url>
  </required_header>
  <id_info>
    <org_study_id>19-1646</org_study_id>
    <nct_id>NCT04679818</nct_id>
  </id_info>
  <brief_title>Intraoperative NOL Titration</brief_title>
  <official_title>Postoperative Consequences of Intraoperative NOL Titration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that intraoperative NOL-guided titration of fentanyl improves initial recovery&#xD;
      characteristics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous work has shown that NOL accurately quantifies nociception during general&#xD;
      anesthesia.6 Presumably, titrating opioids to NOL will therefore provide individual guidance&#xD;
      so that patients will be given about the right amount. Patient given the right amount will&#xD;
      presumably awaken quickly when anesthesia is done, and have good initial pain control in the&#xD;
      PACU. To the extent that NOL titration facilitates optimal opioid dosing, patients are likely&#xD;
      to have better PACU experiences - which would be an important outcome that clinicians and&#xD;
      regulators are likely to take seriously.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores</measure>
    <time_frame>60 minutes</time_frame>
    <description>The investigators will evaluate the pain scores at 10-minute using pain scores (0-10 verbal response scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores &lt;5.</measure>
    <time_frame>60 minutes</time_frame>
    <description>The investigators will evaluate whether or not the pain score at any measured interval is &lt; 5, using (0-10 verbal response scale)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Anesthesia; Adverse Effect</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clinicians will be blinded to PMD-200 NOL monitoring and use clinical judgement to determine how much fentanyl should be given, and when.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PMD-200 NOL group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clinicians will titrate fentanyl to keep PMD-200 NOL under 25 - always using good clinical judgement for individual patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Routine opioid management</intervention_name>
    <description>Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.</description>
    <arm_group_label>PMD-200 NOL group</arm_group_label>
    <other_name>Fentanyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PMD-200 Nol-guided opioid administration</intervention_name>
    <description>PMD-200 NOL values exceeding 25 for more than 30 seconds will typically be treated with boluses of fentanyl 1µg/kg ABW, up to a maximum of 100 µg per boluses, 5-minute intervals. Towards the end of the surgery (approximately 30-45 minutes before end of surgery, based on clinical judgment), the boluses of fentanyl will be reduced to 0.5 µg/kg ABW, up to a maximum of 50 µg per boluses, 5 minutes intervals. The target of a PMD-200 NOL score below 25 will be maintained until surgery ends</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>PMD-200 NOL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults having major non-cardiac surgery expected to last ≥2 hours&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status 1-3&#xD;
&#xD;
          -  Age 21-85 years old&#xD;
&#xD;
          -  Planned endotracheal intubation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Planned neuraxial or regional block&#xD;
&#xD;
          -  Clinician preference for an opioid other than, or in addition to, fentanyl&#xD;
&#xD;
          -  Non-sinus heart&#xD;
&#xD;
          -  Neurologic condition that, in the opinion of the investigators, may preclude accurate&#xD;
             assessment of postoperative pain and nausea&#xD;
&#xD;
          -  Lack of English language fluency&#xD;
&#xD;
          -  Routine user of psychoactive drugs other than opioids&#xD;
&#xD;
          -  Contraindication to sevoflurane, fentanyl, morphine, or ondansetron.&#xD;
&#xD;
          -  Intracranial surgery.&#xD;
&#xD;
          -  BMI &gt; 40&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kurt Ruetzler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberta Johnson</last_name>
    <phone>216-444-9950</phone>
    <email>johnsor13@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mauro Bravo, MD</last_name>
    <email>bravom2@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Johnson</last_name>
      <phone>216-444-9950</phone>
      <email>johnsor13@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Mauro Bravo, MD</last_name>
      <phone>216-444-2936</phone>
      <email>bravom@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kurt Ruetzler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 22, 2020</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

